Mo Jain, MD, PhD

Dr. Mo Jain

Founder & CEO at Sapient

Bio Info

Dr. Jain is a physician-scientist with more than 20 years of expertise in physiology, biomedicine, engineering, computational biology, and mass spectrometry-based metabolomics. He formed and managed Jain Laboratory at the University of California San Diego, where he guided a multi-disciplinary research team to develop next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems to probe the non-genetic landscape of disease across large-scale human studies.


By 2021, Dr. Jain founded Sapient, a discovery metabolomics lab dedicated to accelerating research and sponsor drug programs through rapid, large-scale small molecule biomarker profiling. Combining rLC-MS, an expert data science team, and large-scale human biology datasets, Sapient enables rapid identification of circulating biomarkers of health, disease, and drug responsiveness that are needed to effectively align patients, diseases, and specific therapies.


Booking Dr. Jain would give biopharma professionals working in biomarkers, translational science, precision medicine, and therapeutic areas targeting complex diseases a new perspective on how small molecule biomarkers can applied to advance their drug programs and personalize therapy, and how next-generation technology is enabling their discovery at an entirely new scale – to accelerate drug discovery, transform therapy, and better patient outcomes. Book Dr. Jain now!


Videos

On the Mark: Identifying Non-Invasive Biomarkers of Target Engagement

In this session, Dr. Mohit Jain, Founder and CEO of Sapient, discusses methods for the rapid discovery of small molecule biomarkers of target engagement, leveraging integration of next generation mass spectrometry, genomics, and experimental systems.

What’s Next in Precision Medicine? Small Molecule Biomarkers to Personalize Diagnostics & Therapies

In this webinar, Sapient's Dr. Mo Jain discusses how the mapping of small molecule biomarkers in blood delivers complementary information relative to traditional DNA and protein biomarkers, which can be used in drug development programs to predict disease risk, identify patient subgroups, and create more specific, efficacious therapies aligned with a patient’s unique disease biology.

Previous Interviews

New Matter: Inside the Minds of SLAS Scientists

New Matter: Inside the Minds of SLAS Scientists

Accelerating Human Discovery | A Lesson in Small Molecule Biomarkers with Mo Jain, M.D., Ph.D.

Topic Suggestions

Disruptive tech vs traditional methods in biopharma - A new scale of discovery

Today's role of biomarkers in advancing precision medicine

The pitfalls of drug development and how they should be improved

How to better personalize disease prediction, diagnostics, & therapies

New methods for biomarker discovery, validation, & translation for clinical impact

Specificity at scale - Therapy transformation & drug discovery acceleration

3 reasons genetics alone are not enough to personalize medicine

Next-generation discovery technology – How much more can we find?

Book Speaker Now

Click the button below to reach out to us and let us know!

2 Extra Reasons To Book...

Expert Guests Matter

Our guests have experience appearing on podcasts,

so you don't need to coach them.

Eager to Share

Our guests see the value in appearing on your show,

and they are ready to share their experience

 with their audience - and the world!